scholarly journals Haptoglobin Phenotype Modifies the Effect of Fenofibrate on Risk of Coronary Event: ACCORD Lipid Trial

Diabetes Care ◽  
2021 ◽  
pp. dc211429
Author(s):  
Rachel A. Warren ◽  
Allie S. Carew ◽  
Pantelis Andreou ◽  
Christine Herman ◽  
Andrew P. Levy ◽  
...  
Keyword(s):  
Coronary Event ◽  
Haptoglobin Phenotype

Coronary event after transcatheter pulmonary valve implantation

2012 ◽  
Vol 60 (S 01) ◽  
Author(s):  
D Biermann ◽  
J Schönebeck ◽  
M Rebel ◽  
J Weil ◽  
H Reichenspurner ◽  
...  
Keyword(s):  
Pulmonary Valve ◽  
Coronary Event ◽  
Valve Implantation ◽  
Pulmonary Valve Implantation

139-LB: Haptoglobin Phenotype and Levels in Type 2 Diabetes and Effects of Fenofibrate

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 139-LB
Author(s):  
ANDRZEJ S. JANUSZEWSKI ◽  
HAYDEN K. YOUNG ◽  
LIPING LI ◽  
RACHEL L. OCONNELL ◽  
TIMOTHY LYONS ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Haptoglobin Phenotype

Association between NIDDM, RH blood group, and haptoglobin phenotype. Results from the San Antonio Heart Study

Diabetes ◽  
1986 ◽  
Vol 35 (4) ◽  
pp. 387-391 ◽  
Author(s):  
M. P. Stern ◽  
R. E. Ferrell ◽  
M. Rosenthal ◽  
S. M. Haffner ◽  
H. P. Hazuda
Keyword(s):  
Blood Group ◽  
San Antonio ◽  
Haptoglobin Phenotype ◽  
Heart Study ◽  
Rh Blood Group

Comparison of two recent ceramide-based coronary risk prediction scores: CERT and CERT-2

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
A Leiherer ◽  
A Muendlein ◽  
C.H Saely ◽  
R Laaksonen ◽  
M Laaperi ◽  
...  
Keyword(s):  
Cardiovascular Mortality ◽  
Coronary Event ◽  
Cardiovascular Death ◽  
Survival Models ◽  
Risk Category ◽  
Net Reclassification Improvement ◽  
Event Risk ◽  
Risk Predictor ◽  
Risk Categories

Abstract   The Coronary Event Risk Test (CERT) is a validated cardiovascular risk predictor that uses circulating ceramide concentrations to allocate patients into one of four risk categories. This test has recently been updated (CERT-2), now additionally including phosphatidylcholine concentrations. The purpose of this study was to investigate the power of CERT and CERT-2 to predict cardiovascular mortality in patients with cardiovascular disease (CVD). We investigated a cohort of 999 patients with established CVD. Overall, comparing survival curves (figure) for over 12 years of follow up and the predictive power of survival models using net reclassification improvement (NRI), CERT-2 was the best predictor of cardiovascular mortality, surpassing CERT (NRI=0.456; p=0.01) and also the 2019 ESC-SCORE (NRI=0.163; p=0.04). Patients in the highest risk category of CERT as compared to the lowest category had a HR of 3.63 [2.09–6.30] for cardiovascular death; for CERT-2 the corresponding HR was 6.02 [2.47–14.64]. Among patients with T2DM (n=322), the HR for cardiovascular death was 3.00 [1.44–6.23] using CERT and 7.06 [1.64–30.50] using CERT-2; the corresponding HRs among non-diabetic subjects were 2.99 [1.20–7.46] and 3.43 [1.03–11.43], respectively. We conclude that both, CERT and CERT-2 scores are powerful predictors of cardiovascular mortality in CVD patients, especially in those patients with T2D. Performance is even higher with CERT-2. Funding Acknowledgement Type of funding source: None

scholarly journals Lifestyle and Treatment Adherence Intervention after a Coronary Event Based on an Interactive Web Application (EVITE): Randomized Controlled Clinical Trial Protocol

Nutrients ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 1818
Author(s):  
MªÁngeles Bernal-Jiménez ◽  
Germán Calle-Pérez ◽  
Alejandro Gutiérrez-Barrios ◽  
Livia Gheorghe ◽  
Ana María Solano-Mulero ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Treatment Adherence ◽  
Coronary Event ◽  
Mobile Telephone ◽  
Analysis Of Covariance ◽  
Controlled Clinical Trial ◽  
Randomized Controlled Clinical Trial ◽  
Randomized Controlled

Coronary heart disease is one of the main causes of morbimortality around the world. Patients that survive a coronary event suffer a high risk of readmission, relapse and mortality, attributed to the sub-optimal control of cardiovascular risk factors (CVRF), which highlights the need to improve secondary prevention strategies aimed at improving their lifestyle and adherence to treatment. Through a randomized controlled clinical trial, this study aims to evaluate the effect of an intervention involving an online health application supported by a mobile telephone or tablet (mHealth) on lifestyle (diet, physical activity, and tobacco consumption) and treatment adherence among people with coronary heart disease after percutaneous coronary intervention. The sample will comprise 240 subjects (120 in each arm: intervention and usual care). They are assessed immediately and nine months after their hospital discharge about sociodemographic, clinical, CVRF, lifestyle, and treatment adherence characteristics. The educative intervention, involving a follow-up and self-monitoring, will be performed using an online mHealth tool consisting of an application for mobile phones and tablets. The quantitative primary outcomes from the two groups will be compared using an analysis of covariance (ANCOVA) adjusted for age and gender. A multivariate analysis will be performed to examine the association of the intervention with lifestyle habits, the control of CVRFs, and outcomes after discharge in terms of the use of health services, emergency visits, cardiovascular events and readmissions.

Antiepileptic medications and the risk for sudden cardiac death caused by an acute coronary event: a prospective case-control study

2016 ◽  
Vol 48 (1-2) ◽  
pp. 111-117 ◽  
Author(s):  
Eeva Hookana ◽  
Hanna Ansakorpi ◽  
Marja-Leena Kortelainen ◽  
M. Juhani Junttila ◽  
Kari S Kaikkonen ◽  
...  
Keyword(s):  
Sudden Cardiac Death ◽  
Cardiac Death ◽  
Case Control Study ◽  
Coronary Event ◽  
Case Control ◽  
Acute Coronary Event ◽  
Antiepileptic Medications ◽  
Control Study ◽  
Prospective Case Control Study
Sign in / Sign up

Export Citation Format

Share Document